PETRI DISH PERSPECTIVES

Send us Fan Mail This week on Petri Dish Perspectives , we unpack the story of 23andMe, the company that turned saliva kits into one of the largest human genetic databases in the world and brought genomics out of hospitals and into millions of homes. From its Silicon Valley origins under Anne Wojcicki to its rise as a consumer genetics pioneer backed by major investors, we explore how 23andMe buil...

Send us Fan Mail This week on Petri Dish Perspectives , we’re diving into the story of Thermo Fisher Scientific, the company quietly powering nearly every corner of modern biotechnology. From its origins in scientific instrumentation to becoming a global life sciences infrastructure giant, we explore how Thermo Fisher built an empire through acquisitions, genomics, diagnostics, contract manufactur...

Send us Fan Mail From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives , we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful mechanisms into an entirely new class of medicine. We explore the science behind RNAi, the delivery challenges that nearly killed the field, the lead...

Send us Fan Mail In this episode of Petri Dish Perspectives , we break down the 340B Drug Pricing Program , a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the Health Resources and Services Administration, 340B was designed to help safety-net providers stretch scarce resources and serve vulnerable patients. But...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for April 2026! This month was dominated by a high-stakes pivot toward oral obesity treatments, a massive consolidation of precision oncology platforms like ADCs and radiopharmaceuticals, and a structural shift toward AI-native drug discovery and in-vivo genomic medicine. 🎧 Listen now, stay curi...

Send us Fan Mail What if cancer treatment wasn’t a drug but a living, evolving system inside your body? In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy . From its origins in academic labs to billion-dollar acquisitions by companies like Gilead Sciences, Bristol Myers Squibb, and Novartis, CAR-T represents a fundamental shift, from tre...

Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed , we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most dominant players in modern oncology. This isn’t your typical biotech story. There’s no overnight success, no single “eureka” moment. Instead, we trace a century-long evolution, from...

Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed , we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies in oncology: antibody-drug conjugates (ADCs). From its early days as a Dana-Farber spinout to decades of scientific setbacks, market skepticism, and near-collapse moments, ImmunoG...

Send us Fan Mail In this episode of Petri Dish Perspectives, we’re dissecting the "Phoenix of Biotech." On March 23, 2026, the era of Exact Sciences as an independent company officially ended with its massive $23 billion acquisition by Abbott Laboratories. But the road to this exit wasn't paved with easy wins, it was forged in the wreckage of a "zombie" penny stock that al...

Send us Fan Mail In this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D costs and an explosion of biological data, and how the industry has transitioned from a "serendipity-based" model to one of predictive, generative biology. We break down...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026! This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued GLP-1 challenges. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Suppo...

Send us Fan Mail In this episode of Petri Dish Perspectives , we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in the world, we explore how the company positioned itself not as a traditional biotech, but as a “organism engineering foundry.” We break down Ginkgo’s unique business model, partneri...

Send us Fan Mail From a small operation built on just ₹10,000 to a global pharmaceutical powerhouse, Sun Pharmaceutical Industries is one of the most compelling growth stories in modern biotech. In this episode of Petri Dish Perspectives: Biotech Unleashed , we break down how Dilip Shanghvi transformed a niche generics business into one of the largest pharmaceutical companies in the world. We expl...

Send us Fan Mail In this episode of Petri Dish Perspectives , we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit foundation. Founded in 1954 by the physician-pharmacist Jacques Servier, the company grew from a tiny laboratory in Orléans into a global powerhouse in cardiovascular and metabolic...

Send us Fan Mail Most biotech companies chase massive markets. But BioMarin Pharmaceutical built its entire strategy around something very different: ultra-rare genetic diseases affecting only small patient populations around the world. In this episode of Petri Dish Perspectives: Biotech Unleashed , we break down how BioMarin became one of the most influential rare-disease biotech companies in the...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for February 2026! This month was dominated by by three massive themes: The Great IPO Thaw, the "AI Factory" Era, and Regulatory Hardball. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #Pharm...

Send us Fan Mail Before the world knew the power of mRNA vaccines, BioNTech was a relatively quiet biotech company focused on one ambitious goal: curing cancer through the immune system. Then the COVID-19 pandemic changed everything. In this episode of Petri Dish Perspectives: Biotech Unleashed , we explore how BioNTech evolved from an academic vision into one of the most important biotechnology c...

Send us Fan Mail In this episode of Petri Dish Perspectives , we unpack the strategy and scientific conviction behind ARCH Venture Partners , the venture firm that has quietly helped build some of the most transformative companies in modern biotechnology. From early bets on platform technologies like gene editing and mRNA to backing next-generation leaders such as Juno , Editas Medicine , Beam The...

Send us Fan Mail In this episode of Petri Dish Perspectives , we explore the fascinating evolution of Otsuka Holdings , a company that defies traditional pharmaceutical stereotypes. From its origins in Japan as a chemical and nutrition-focused business to becoming a global biopharma innovator, Otsuka has built its reputation by targeting complex and often misunderstood disease areas such as psychi...

Send us Fan Mail What if medicine could fix disease at its source… by rewriting the genetic code itself? In this episode of Petri Dish Perspectives , we dive into the incredible story of gene therapy , one of the most ambitious and transformative frontiers in modern medicine. From early scientific discoveries about DNA and viral delivery systems, to heartbreaking clinical setbacks that nearly shut...

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026! This month was dominated by a surge in Eli Lilly's deals, partnerships, etc.  🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bu...

Send us Fan Mail What does it take to spend decades chasing one of medicine’s hardest problems while the rest of the industry walks away? In this episode, we explore the remarkable story of Eisai , the Japanese pharmaceutical company that built its global identity around Alzheimer’s disease. From its founding during World War II and early commitment to ethical medicine, to the blockbuster success...

Send us Fan Mail Flagship Pioneering doesn’t wait for scientific breakthroughs. It builds them. In this episode, we dive deep into the origin story of one of the most influential venture creation firms in biotech and the mind behind it, Noubar Afeyan. From his early life shaped by uncertainty to the founding of a firm that treats biology like an engineering discipline, we explore how Flagship rede...

Send us Fan Mail Biogen is one of the most influential and controversial companies in modern biotechnology. Founded in the late 1970s by Nobel-level scientists who believed recombinant DNA would redefine medicine, Biogen helped turn neurology into a commercial field long before most pharma companies dared to enter it. In this episode, we trace Biogen’s full journey, from its academic origins and t...

Send us Fan Mail Theranos promised to revolutionize healthcare with a single drop of blood and became one of the most infamous failures in biotech history.  In this episode, we trace the full rise and fall of Elizabeth Holmes and Theranos, from its founding in 2003 to its dramatic collapse and criminal convictions nearly two decades later. We explore how ambition, secrecy, and Silicon Valley mytho...